CXCR4 and cancer: Utilizing our hydrogel assay system, patient-derived breast cancer cells were treated with a receptor-blocking antagonist directed against CXCR4 alone or in combination with neutralizing antibody directed against CXCL16 and tested for cancer cell migration to brain metastatic CAF aggregates.